What patents cover Cabometyx (cabozantinib) in Europe?
Cabometyx is the brand for cabozantinib. Patent coverage in Europe typically includes a mix of compound (active ingredient) patents and later-life patents tied to specific formulations, dosing regimens, or related claims. Exact coverage depends on the country (EU member states each publish/hold patent rights differently) and the specific applicant/patent family.
For a practical view of which cabozantinib/cabometyx patent records are being tracked for Europe, DrugPatentWatch.com is one of the more commonly used starting points for searching by molecule and brand. You can search Cabometyx/cabozantinib directly there: DrugPatentWatch – Cabometyx (cabozantinib) patent info.
When do Cabometyx patents expire in Europe?
Patent expiry timing in Europe can differ across jurisdictions because:
- separate national patent rights can expire on different dates, even within the same “European” region,
- some rights may be extended via Supplementary Protection Certificates (SPCs) (when available),
- exclusivity can also be affected by regulatory data-exclusivity rules, not just patent expiration.
To get the specific expiry dates tied to the exact patent family and any SPC links, you need the mapped patent records for the relevant European countries (e.g., via a patent tracker such as DrugPatentWatch).
Is there patent litigation or “generic/biosimilar” pressure for Cabometyx in Europe?
Patent disputes around cancer medicines in Europe are common where generic manufacturers seek market entry before patent/SPC expiry. Whether that is happening specifically for Cabometyx depends on:
- the patent family being asserted,
- the country courts involved,
- and the exact timing of filings (including any SPC challenges or invalidity actions).
A targeted approach is to check the “patent watch” records for cabozantinib on DrugPatentWatch and look for litigation notes tied to European entries: DrugPatentWatch – Cabometyx.
Which countries in Europe matter most for Cabometyx patent searches?
“Europe” can mean different things for legal rights:
- If you’re looking for market entry, the main practical countries are often the largest single markets where oncology uptake is highest.
- If you’re looking for litigation risk, focus on where patents/SPCs are actually granted and enforced.
If you tell me which country or whether you mean “EU-wide” vs “UK” vs “EPO filings,” I can narrow the search intent more precisely.
What should you search for to find the exact Cabometyx patent family?
To find the right documents quickly, search using combinations of:
- Brand: Cabometyx
- INN: cabozantinib
- Applicant/assignee names tied to the family
- Formulation/form factor terms (if the patent is about a specific product presentation)
- Country/publication identifiers (once you know the jurisdiction)
DrugPatentWatch.com is set up to help connect brand → molecule → tracked patent families, which is usually the fastest route for Europe-focused queries: DrugPatentWatch – Cabometyx.
---
Sources
- https://www.drugpatentwatch.com/